ArticleFrontiers in oncology2026
Phenotypic, functional and metabolic features of B cells from a small cohort of breast cancer patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objective: Identify and characterize breast cancer (BC)-induced changes of humoral immunity and B cell function in a small cohort of treatment-naïve breast cancer patients (BCPs) as compared to healthy controls (HCs). Methods: The peripheral blood from newly diagnosed, treatment-naive breast cancer patients (BCPs) and age-matched cancer-free individuals (HCs) was collected. B cells were isolated and cellular, molecular, functional and metabolic analyses were performed. Results: There is a redistribution of B cell subsets in the blood of BCPs versus HCs with increased frequencies of pro-inflammatory B cell subsets in BCPs. B cells from BCPs secrete higher amounts of pro-inflammatory cytokines than B cells from HCs, due to the activation of the transcription factor NF-kB. B cells from BCPs also secrete high amounts of the metabolite lactate and are highly glycolytic, as shown in a Seahorse mitostress test. This hyper-metabolic phenotype can be inhibited at least Conclusion: Results have identified a set of distinct and significant changes in the circulating B cells of our cohort of BCPs that may help to establish a baseline B cell signature of BCPs before therapy, to predict B cell performance during therapy by identifying immunosuppressive cells, and to design precision therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.